Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis

Filippo Pietrantonio, Fausto Petrelli, Andrea Coinu, Maria Di Bartolomeo, Karen Borgonovo, Claudia Maggi, Mary Cabiddu, Roberto Iacovelli, Ilaria Bossi, Veronica Lonati, Mara Ghilardi, Filippo De Braud, Sandro Barni

Research output: Contribution to journalArticlepeer-review


Abstract Background Wild type RAS (RAS-wt) status is predictive of the activities of the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (C) and panitumumab (P). We examined the impact of C and P on progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) in advanced colorectal cancer (CRC) patients who have RAS-wt/BRAF-mutant (BRAF-mut) status. Methods Randomised trials that compared C or P plus chemotherapy (or C or P monotherapy) with standard therapy or best supportive care (BSC) were included. We used published hazard ratios (HRs) if they were available, or we derived treatment estimates from other survival data. Pooled estimates of the treatment efficacy of anti-EGFR-based therapy with C or P for the RAS-wt/BRAF-mut subgroup were calculated with the random-effect inverse variance weighted method. All statistical tests were two-sided. Results Nine phase III trials and one phase II trial (six first-line and two second-line trials, plus two trials involving chemorefractory patients), that included 463 RAS-wt/BRAF-mut CRC patients, were analysed. Overall, the addition of C or P treatment in the BRAF-mut subgroup did not significantly improve PFS (HR, 0.88; 95% confidence interval (CI), 0.67-1.14; p = 0.33), OS (HR, 0.91; 95% CI, 0.62-1.34; p = 0.63) and ORR (relative risk, 1.31; 95% CI 0.83-2.08, p = 0.25) compared with control regimens. Conclusions C- or P-based therapy did not increase the benefit of standard therapy or the BSC in RAS-wt/BRAF-mut CRC patients. These findings support BRAF mutation assessment before initiation of treatment with anti-EGFR monoclonal antibodies.

Original languageEnglish
Article number9390
Pages (from-to)587-594
Number of pages8
JournalEuropean Journal of Cancer
Issue number5
Publication statusPublished - 2015


  • BRAF mutation
  • Cetuximab
  • Colorectal cancer
  • Meta-analysis
  • Panitumumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)


Dive into the research topics of 'Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis'. Together they form a unique fingerprint.

Cite this